Inflammatory and tumor-associated serum biomarkers, such as carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), and cancer antigen 125, may refine prognostic assessment. The gene discussed is MUC16; the disease is neoplasm.